Does Inotiv (NOTV) Have a Profitable Business Model?

Shares of Small-cap Diagnostics & Research company Inotiv were up 14.2% Friday, as the S&P 500 posted a 0.6% change. Last week's upwards movement shows that investor interest in NOTV stock is strong -- but how closely have they studied the company's margins?

While Inotiv's gross margins for the last year are positive, we are concerned that the company's operating margins are in the red. Gross margins take into account only the cost of revenue, or variable costs -- meaning the cost directly associated with producing the products or providing the service offered by the company.

Operating margins, on the other hand, take into account the company's overhead as well. Overhead, also called fixed costs, includes the company's rent, salaries for personnel not included in cost of revenue, equipment and supplies, amortization, and depreciation. Operating margins tell you about how efficiently Inotiv is run, and gross margins tell you how profitable its product line is.

Date Reported Revenue ($ MM) Cost of Revenue ($ MM) Gross Margins (%) YoY Growth (%)
2021-09-30 90 59 33.65 11.57
2020-09-30 60 42 30.16 1.82
2019-09-30 44 31 29.62 n/a

Since Inotiv's cost of revenue is growing at an average 93.7% per year, while its total revenues have a 43.4% growth rate, the only explanation for the widening margins is that the company is increasing its prices. Since prices cannot be increased indefinitely, Inotiv's gross margin growth will eventually slow unless it can get its cost of revenue under control.

Date Reported Total Revenue ($ MM) Operating Expenses ($ MM) Operating Margins (%) YoY Growth (%)
2021-09-30 90 36 -6.27 -23.67
2020-09-30 60 21 -5.07 -1348.57
2019-09-30 44 13 -0.35 n/a

The table above tells us that, on average, Inotiv has not been profitable over the last four years, which should be a warning sign to prospective investors. Indeed, the company's operating margins are sinking at rate of -686.1%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.